Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients

• Main Authors: Chung, Hyun Cheol, Kang, Yoon-Koo, Chen, Zhendong, Bai, Yuxian, Ishak, Wan Zamaniah Wan, Shim, Byoung Yong, Park, Young Lee, Koo, Dong-Hoe, Lu, Jianwei, Xu, Jianming, Chon, Hong Jae, Bai, Li-Yuan, Zeng, Shan, Yuan, Ying, Chen, Yen-Yang, Gu, Kangsheng, Zhong, Wen Yan, Kuang, Shu, Shih, Chie-Schin, Qin, Shu-Kui
• Format: Article
• Published: Wiley 2022
• Subjects: RC Internal medicine; RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://eprints.um.edu.my/33657/

Background KEYNOTE-063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second-line therapy in Asian patients with advanced programmed death ligand 1 (PD-L1)-positive (combined positive score >= 1) gastric/gastroesophageal junction (GEJ) cancer. Methods This randomized, open-label, p...